ISPC Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -156.82% compared to iSpecimen's net margin of 5.4%. iSpecimen's return on equity of -249.02% beat Delcath Systems's return on equity of -40.28%.

iSpecimen has a consensus price target of --, signalling upside risk potential of 5209.74%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 53.95%. Given that iSpecimen has higher upside potential than Delcath Systems, analysts believe iSpecimen is more attractive than Delcath Systems.

iSpecimen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.238%.

iSpecimen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

iSpecimen quarterly revenues are $1.1M, which are smaller than Delcath Systems quarterly revenues of $19.8M. iSpecimen's net income of -$1.7M is lower than Delcath Systems's net income of $1.1M. Notably, iSpecimen's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen is 0.18x versus 9.60x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

23andMe Holding has a net margin of -156.82% compared to iSpecimen's net margin of --. iSpecimen's return on equity of -249.02% beat 23andMe Holding's return on equity of --.

iSpecimen has a consensus price target of --, signalling upside risk potential of 5209.74%. On the other hand 23andMe Holding has an analysts' consensus of -- which suggests that it could fall by -59.61%. Given that iSpecimen has higher upside potential than 23andMe Holding, analysts believe iSpecimen is more attractive than 23andMe Holding.

iSpecimen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison 23andMe Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iSpecimen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 23andMe Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen pays -- of its earnings as a dividend. 23andMe Holding pays out -- of its earnings as a dividend.

iSpecimen quarterly revenues are $1.1M, which are larger than 23andMe Holding quarterly revenues of --. iSpecimen's net income of -$1.7M is higher than 23andMe Holding's net income of --. Notably, iSpecimen's price-to-earnings ratio is -- while 23andMe Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen is 0.18x versus 0.62x for 23andMe Holding. Usually stocks with elevated PS ratios are considered overvalued.

RadNet has a net margin of -156.82% compared to iSpecimen's net margin of -8.05%. iSpecimen's return on equity of -249.02% beat RadNet's return on equity of -2.91%.

iSpecimen has a consensus price target of --, signalling upside risk potential of 5209.74%. On the other hand RadNet has an analysts' consensus of $71.57 which suggests that it could grow by 27.25%. Given that iSpecimen has higher upside potential than RadNet, analysts believe iSpecimen is more attractive than RadNet.

iSpecimen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RadNet has a beta of 1.429, suggesting its more volatile than the S&P 500 by 42.944%.

iSpecimen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RadNet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen pays -- of its earnings as a dividend. RadNet pays out -- of its earnings as a dividend.

iSpecimen quarterly revenues are $1.1M, which are smaller than RadNet quarterly revenues of $471.4M. iSpecimen's net income of -$1.7M is higher than RadNet's net income of -$37.9M. Notably, iSpecimen's price-to-earnings ratio is -- while RadNet's PE ratio is 1,513.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen is 0.18x versus 2.30x for RadNet. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -156.82% compared to iSpecimen's net margin of -9.1%. iSpecimen's return on equity of -249.02% beat Star Equity Holdings's return on equity of -15.99%.

iSpecimen has a consensus price target of --, signalling upside risk potential of 5209.74%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 316.67%. Given that iSpecimen has higher upside potential than Star Equity Holdings, analysts believe iSpecimen is more attractive than Star Equity Holdings.

iSpecimen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 1.002, suggesting its more volatile than the S&P 500 by 0.203%.

iSpecimen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

iSpecimen quarterly revenues are $1.1M, which are smaller than Star Equity Holdings quarterly revenues of $12.9M. iSpecimen's net income of -$1.7M is lower than Star Equity Holdings's net income of -$1.2M. Notably, iSpecimen's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen is 0.18x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.